Trials
1 active
9 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Phase 1 (Days 1-10): Mexidol® solution, 500 mg (10 ml) twice daily (total daily dose 1000 mg) administered via IV infusion in 100-200 ml of 0.9% NaCl solution for 10 days. Infusion rate: 40-60 drops per minute. Phase 2 (Days 11-70): Mexidol® FORTE 250 film-coated tablets, 250 mg three times daily (total daily dose 750 mg) for 60 days. Administered on top of standard background therapy in…”In the company’s words, NCT07575984 on ClinicalTrials.gov
- Tested for
- Ischemic Stroke
- Main trialPhase 4
- “The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.”In the company’s words, NCT07575984 on ClinicalTrials.gov
- Other names
- Ethylmethylhydroxypyridine Succinate
Other drugs for Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up1
- Apr 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Apr 2027 | Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke | |
| Phase 4Completed | 12 Sep 2023 | MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure | |
| Phase 4Completed | 29 Nov 2023 | MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) | |
| Phase 4Completed | 5 Nov 2025 | Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults | |
| Phase 3Completed | 27 May 2016 | Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy | |
| Phase 3Completed | 13 Jul 2020 | Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 | |
| Phase 3Completed | 8 Dec 2020 | Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia | |
| Phase 3Completed | 18 Aug 2023 | Efficacy and Safety of Mexidol® in Stroke Therapy | |
| Phase 2Completed | 7 Sep 2023 | Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026